Page 2

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Trump threatens tariffs on imported generic drugs

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove more disruptive.

Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.

Crystalys nets $130M more to push gout drug through late-stage tests

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.

Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

Novartis climbs on upbeat drug sales as key readouts loom

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

Agios scraps sickle cell drug

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

Pain drugmaker Latigo outlines plans to go public

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

Tempus to acquire cancer test maker Personalis for $1.5B

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

GSK shelves cough drug acquired in $2B deal

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

Merck wins first approval of a PCSK9 cholesterol pill

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.  

Updated July 16, 2026

Biotech startup funding gap widens despite rebound in VC investment

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.

How well are AI-discovered drugs faring in the clinic?

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

Jasper gets a lifeline in merger with immune drugmaker Kira

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.  

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

Merck ADC, in China study, shows potential to replace chemo in lung cancer

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer. 

Celcuity gains FDA approval for closely watched breast cancer drug

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Updated July 15, 2026

Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

Braveheart, Attovia join next wave of biotech IPOs

The heart drug developer and immune disease specialist aim to capitalize on momentum that’s already yielded several big-ticket IPOs this year.

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

Judge orders Apple Tree partner to forfeit oversight of venture fund

The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.

Updated July 14, 2026